Insider Buying: Cardiff Oncology, Inc. (NASDAQ:CRDF) Director Purchases $910,299.00 in Stock

Cardiff Oncology, Inc. (NASDAQ:CRDF) Director Gary W. Pace bought 350,115 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was bought at an average price of $2.60 per share, with a total value of $910,299.00. Following the acquisition, the director now directly owns 1,047,876 shares in the company, valued at $2,724,477.60. The trade was a 50.18 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Cardiff Oncology Trading Up 19.9 %

Shares of NASDAQ CRDF opened at $3.92 on Friday. The stock has a market cap of $200.43 million, a P/E ratio of -4.17 and a beta of 1.89. The business’s fifty day simple moving average is $2.89 and its 200-day simple moving average is $2.61. Cardiff Oncology, Inc. has a 12-month low of $1.27 and a 12-month high of $6.42.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Piper Sandler raised their price target on Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a research report on Friday. HC Wainwright dropped their target price on Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating for the company in a research report on Friday, November 8th. Finally, Craig Hallum began coverage on shares of Cardiff Oncology in a research report on Friday, September 6th. They set a “buy” rating and a $8.00 price target on the stock.

Institutional Investors Weigh In On Cardiff Oncology

A number of hedge funds have recently bought and sold shares of the stock. Point72 DIFC Ltd purchased a new stake in shares of Cardiff Oncology during the second quarter worth approximately $27,000. Ground Swell Capital LLC acquired a new position in Cardiff Oncology during the 2nd quarter worth approximately $38,000. Dimensional Fund Advisors LP increased its position in shares of Cardiff Oncology by 34.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 19,098 shares of the company’s stock valued at $42,000 after purchasing an additional 4,892 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Cardiff Oncology in the 3rd quarter valued at $64,000. Finally, Invst LLC purchased a new stake in shares of Cardiff Oncology during the 2nd quarter worth $74,000. Institutional investors and hedge funds own 16.29% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.